Hind Medyouf

1.9k total citations
23 papers, 976 citations indexed

About

Hind Medyouf is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Hind Medyouf has authored 23 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Hind Medyouf's work include Acute Myeloid Leukemia Research (8 papers), Hematopoietic Stem Cell Transplantation (4 papers) and CAR-T cell therapy research (3 papers). Hind Medyouf is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Hematopoietic Stem Cell Transplantation (4 papers) and CAR-T cell therapy research (3 papers). Hind Medyouf collaborates with scholars based in Germany, France and Canada. Hind Medyouf's co-authors include Jacques Ghysdael, Henner F. Farin, Andrew P. Weng, Birgitta E. Michels, Samuel Gusscott, Françoise Pflumio, Anne Janin, Hugues de Thé, Didier Decaudin and Nuno R. dos Santos and has published in prestigious journals such as Nature Medicine, The Journal of Experimental Medicine and The Journal of Cell Biology.

In The Last Decade

Hind Medyouf

23 papers receiving 961 citations

Peers

Hind Medyouf

ONCOL

HEMAT

IMMUN

Frédéric Barabé Canada

Zhaodong Zhong China

Yasuhiko Kamikubo Japan

Francesco Paolo Tambaro United States

Sagi Abelson Canada

Catherine Frelin Canada

Shuwei Jiang United States

Seiichi Okabe Japan

Yixiao Gong United States

Youshan Zhao China

Frédéric Barabé Canada

Hind Medyouf

732 ×1.4

286 ×1.0

ONCOL

416 ×1.7

HEMAT

348 ×1.6

IMMUN

132 ×0.8

Citations per year, relative to Hind Medyouf Hind Medyouf (= 1×) peers Frédéric Barabé

Countries citing papers authored by Hind Medyouf

Since Specialization

Citations

This map shows the geographic impact of Hind Medyouf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hind Medyouf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hind Medyouf more than expected).

Fields of papers citing papers by Hind Medyouf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hind Medyouf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hind Medyouf. The network helps show where Hind Medyouf may publish in the future.

Co-authorship network of co-authors of Hind Medyouf

This figure shows the co-authorship network connecting the top 25 collaborators of Hind Medyouf. A scholar is included among the top collaborators of Hind Medyouf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hind Medyouf. Hind Medyouf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Winter, Susann, Katharina S. Götze, Judith S. Hecker, et al.. (2024). Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche. Leukemia. 38(5). 936–946. 13 indexed citations

Prinz, Vincent, Konstantinos D. Kokkaliaris, Hind Medyouf, et al.. (2023). The Brain Pre-Metastatic Niche: Biological and Technical Advancements. International Journal of Molecular Sciences. 24(12). 10055–10055. 11 indexed citations

Saini, Sunil Kumar, Anne-Mette Bjerregaard, Ashwin Unnikrishnan, et al.. (2022). Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies. Leukemia. 36(11). 2734–2738. 4 indexed citations

Passaro, Diana, et al.. (2021). NFAT transcription factors are essential and redundant actors for leukemia initiating potential in T-cell acute lymphoblastic leukemia. PLoS ONE. 16(7). e0254184–e0254184. 6 indexed citations

Tirado‐González, Irene, Adrian Contreras, Irmela Jeremias, et al.. (2020). Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia. 35(1). 294–294. 2 indexed citations

Varga, Júlia, Adele M. Nicolas, Valentina Petrocelli, et al.. (2020). AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer. The Journal of Experimental Medicine. 217(10). 57 indexed citations

Michels, Birgitta E., Mohammed H. Mosa, Tianzuo Zhan, et al.. (2020). Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids. Cell stem cell. 26(5). 782–792.e7. 170 indexed citations

Medyouf, Hind. (2017). The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. Blood. 129(12). 1617–1626. 90 indexed citations

Botezatu, Lacramioara, Lars Michel, Charles Vadnais, et al.. (2016). Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. Experimental Hematology. 44(8). 713–726.e14. 12 indexed citations

10.

Kolodziej, Stephan, Olga N. Kuvardina, Julia Herglotz, et al.. (2016). MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO. PLoS Genetics. 12(3). e1005946–e1005946. 21 indexed citations

11.

Rauner, Martina, Hind Medyouf, Igor Theurl, et al.. (2014). Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia. 29(2). 259–268. 58 indexed citations

12.

Ehninger, Armin, Tobias Boch, Hind Medyouf, et al.. (2014). Loss of SPARC protects hematopoietic stem cells from chemotherapy toxicity by accelerating their return to quiescence. Blood. 123(26). 4054–4063. 26 indexed citations

13.

Medyouf, Hind, Samuel Gusscott, Hongfang Wang, et al.. (2011). High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. The Journal of Cell Biology. 194(3). i8–i8. 4 indexed citations

14.

Medyouf, Hind, Samuel Gusscott, Hongfang Wang, et al.. (2011). High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. The Journal of Experimental Medicine. 208(9). 1809–1822. 131 indexed citations

15.

Giambra, Vincenzo, Oksana Nemirovsky, Sonya H.L. Lam, et al.. (2010). Notch-Mediated Suppression of PKCθ Reduces Reactive Oxygen Species and Promotes Leukemic Stem Cell Activity In T-Cell Acute Lymphoblastic Leukemia (T-ALL). Blood. 116(21). 12–12. 3 indexed citations

16.

Medyouf, Hind, Xiuhua Gao, Florence Armstrong, et al.. (2009). Acute T-Cell Leukemias Remain Dependent On Notch Signaling Despite PTEN and INK4A/ARF Loss.. Blood. 114(22). 8–8. 7 indexed citations

17.

Medyouf, Hind, Xiuhua Gao, Florence Armstrong, et al.. (2009). Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood. 115(6). 1175–1184. 65 indexed citations

18.

Medyouf, Hind & Jacques Ghysdael. (2008). The calcineurin/NFAT signaling pathway: A NOVEL therapeutic target in leukemia and solid tumors. Cell Cycle. 7(3). 297–303. 90 indexed citations

19.

Medyouf, Hind, Caroline Berthier, Nuno R. dos Santos, et al.. (2007). Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nature Medicine. 13(6). 736–741. 124 indexed citations

20.

Joliot, Véronique, et al.. (2006). Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis. Oncogene. 25(33). 4573–4584. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact